- Details
-
Category: Technology Trends
Cadilla Pharmaceuticals and US based biotech firm Novavax has formed a 80:20 joint-venture to conduct research and commercializing virus-like-particle (VLP) based vaccines. It seems, Cadilla will invest USD 8 million and Novavax will bring the technology. The deal will also help to commercialize Cadilla’s therapeutic vaccine candidates against cancer as well adjutants, bio generic products in India.
It has formed CPL Biologicals Private Limited, a new joint venture company and plans to set up a new ‘Virus Like Particles’ (VLP) plant by 2011. Currently, it operates from CPL existing unit and it may have its own unit by two years time. VLP technology will help to reduce vaccine making time by 50% and the new plant may entail investment of Rs.1000 million. It will focus to produce H1N1 influenza vaccine (also called swine flu vaccine).
